-
Cyclosporin A: From Mechanism to Translation
2026-09-20
Cyclosporin A is more than a conventional calcineurin inhibitor: it is a context-dependent probe of cyclophilin, NFAT, MAPK, and mitochondrial biology. This thought-leadership guide connects its mechanistic architecture with causal experimental design, translational controls, and the limits of extending immunology insights into neuroscience.
-
Bufalin–CRISPR Nanomedicine for Colorectal Cancer
2026-09-19
Liu and colleagues developed a calcium lactate nanoparticle that co-delivers bufalin and CRISPR/Cas9 ribonucleoproteins targeting CD47, linking tumor-cell death with macrophage reprogramming and immune checkpoint disruption. The study reports coordinated pyroptosis, apoptosis, M1-like macrophage polarization, enhanced phagocytosis, and systemic antitumor activity, while also highlighting the translational challenges of combining nanomedicine with genome editing.
-
S63845 MCL1 Inhibitor: Workflow & Applications
2026-09-18
S63845 is a high-affinity MCL1 inhibitor for dissecting mitochondrial apoptosis in hematological and selected solid-tumor models. This practical guide connects dose-response design, BAX/BAK-dependent apoptosis readouts, and combination workflows inspired by recent pancreatic cancer research.
-
P2Y11 Antagonist NF 340 in Invasion Assays
2026-09-18
NF 340 provides a practical way to test whether P2Y11-linked GPCR signaling contributes to breast cancer cell migration, invasion, and myosin light-chain phosphorylation. This guide translates the QPRT–P2Y11 findings into controlled workflows, dose-finding strategies, and troubleshooting steps while separating established evidence from optimization recommendations.
-
WDR36, Glycolysis, and Human Trophectoderm Fate
2026-09-17
The reference study identifies WDR36 as a regulator of human blastoid formation and trophectoderm commitment, linking this developmental function to glucose metabolism and interaction with LDHA. Its combined use of mouse embryos, human pluripotent stem cell-derived blastoids, transcriptomics, and targeted metabolomics provides a mechanistic framework for studying early developmental arrest.
-
ISG20 and CLEC5A in Atherosclerosis: Causal Evidence
2026-09-17
Zhang and colleagues integrated GEO expression data, eQTL evidence, Mendelian randomization, and experimental validation to examine whether immune-associated genes causally influence atherosclerosis. The study highlights ISG20 as a candidate regulator of macrophage lipid accumulation and plaque inflammation while illustrating how genetic inference can prioritize targets for mechanistic follow-up.
-
Pertussis toxin for reproducible immune assays
2026-09-16
This scenario-driven guide explains how Pertussis toxin, SKU B7273, can be incorporated into cell viability, proliferation, and immune-modulation workflows without confusing pathway effects with nonspecific cytotoxicity. It covers assay design, protocol handling, interpretation, and practical vendor-selection criteria for biomedical laboratories.
-
H2S Deficiency and ER Stress in Diabetic Cardiomyopathy
2026-09-16
Guo et al. connected reduced endogenous hydrogen sulfide production with palmitate-associated lipotoxicity, endoplasmic reticulum stress, and myocardial injury in diabetic cardiomyopathy. By combining patient samples, a streptozotocin-induced rat model, and AC16 cardiomyocytes, the study showed that H2S donation and ER-stress inhibition reduced lipid accumulation and apoptosis, while also defining important limits for translating bulk H2S measurements into dynamic cellular imaging.
-
Chloroquine in Cancer Therapy: Pharmacology and Evidence
2026-09-15
This review reframes Chloroquine as more than an autophagy inhibitor by integrating lysosomal, apoptotic, necroptotic, and signaling mechanisms relevant to cancer therapy. It also evaluates combination strategies, safety considerations, and the experimental controls needed to distinguish autophagy-dependent effects from broader pharmacology.
-
Ruxolitinib in Anaplastic Thyroid Cancer: Study Insights
2026-09-15
The reference study identifies a previously underappreciated connection between JAK1/2-STAT3 signaling and DRP1-dependent mitochondrial fission in anaplastic thyroid carcinoma. Its data indicate that ruxolitinib can promote caspase-dependent apoptosis and GSDME-mediated pyroptosis by suppressing STAT3-driven DRP1 transcription, providing a mechanistic basis for further preclinical investigation.
-
MK-0812 for CCR2 and MASH Research
2026-09-14
Use MK-0812 to isolate CCR2-dependent monocyte trafficking from the gut–liver mechanisms implicated in MASH. This workflow combines human whole-blood pharmacology, immune-cell flow cytometry, chemotaxis assays, and TM6SF2-centered mouse models to connect target engagement with tissue inflammation.
-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-09-14
Qiu et al. show that phenothiazines strengthen macrophage antibacterial activity through increased lysosomal activity, reactive oxygen species (ROS), and autophagy. Pharmacological inhibition of autophagy or ROS weakened the response, while perphenazine reduced pathology in a Salmonella Typhimurium infection model, supporting phenothiazines as host-directed therapy leads.
-
Chloroquine Workflows for Autophagy and Cancer Research
2026-09-13
Build reproducible Chloroquine experiments around lysosomal pH, autophagic flux, inflammatory signaling, and orthogonal cancer readouts. This guide translates the TQB3720 ferroptosis study into practical assay choices without confusing a mechanistic comparator with proof of Chloroquine activity.
-
SB 431542: From ALK5 Biology to Translation
2026-09-12
A translational guide to using SB 431542 as an ALK5 inhibitor, connecting TGF-β/Smad2 biology, glioma and tumor-immunity evidence, and a human iPSC-derived sensory-neuron model for disciplined experimental strategy.
-
Ruxolitinib Phosphate: From JAK Signals to Cell Fate
2026-09-11
Ruxolitinib phosphate (INCB018424) offers translational researchers a precise way to interrogate JAK1/JAK2-dependent cytokine biology, while emerging evidence in anaplastic thyroid carcinoma connects JAK/STAT signaling pathway modulation to mitochondrial dynamics, apoptosis, and GSDME-dependent pyroptosis. This article translates that mechanistic insight into practical study design, product-handling guidance, and a framework for evaluating pathway inhibitors beyond conventional product-page claims.